United States: Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar - Goodwin Procter LLP

Friday, 15 March 2024
On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson ("J&J") regarding Bmab 1200, Biocon's proposed biosimilar to STELARA.

👓 View full article

0 shares	Share Tweet Save Post Send

Related videos from verified sources

Nvidia & darpa biohybrid

https://www.youtube.com/watch?v=0Hg7XhbXuac . No One is Talking About What Just Happened..

Credit: Rumble Duration: 55:45Published on March 29, 2024

United States: Biocon Settles With Bayer And Regeneron, Securing Canada Market Entry Date For Aflibercept Biosimilar - Goodwin Procter LLP

On March 4, Biocon Biologics Ltd. announced it has signed a settlement agreement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. regarding YESAFILI, Biocon's...
Mondaq on March 15, 2024

United States: Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar - Goodwin Procter LLP

You Might Like

Related videos from verified sources

Related news from verified sources

United States: Biocon Settles With Bayer And Regeneron, Securing Canada Market Entry Date For Aflibercept Biosimilar - Goodwin Procter LLP